J
Judith L. Treadway
Researcher at Pfizer
Publications - 59
Citations - 2814
Judith L. Treadway is an academic researcher from Pfizer. The author has contributed to research in topics: Glycogen phosphorylase & Glycogen. The author has an hindex of 28, co-authored 59 publications receiving 2692 citations.
Papers
More filters
Journal ArticleDOI
Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus.
TL;DR: Current evidence indicates that glycogenolysis is an important contributor to the abnormally high production of glucose by the liver, which has bolstered interest and promise in glycogen phosphorylase inhibitors (GPIs) as potential new hypoglycaemic agents for treatment of type 2 diabetes mellitus.
Journal ArticleDOI
Discovery of a human liver glycogen phosphorylase inhibitor that lowers blood glucose in vivo
William H. Martin,Dennis J. Hoover,Sandra J Armento,Ingrid A. Stock,R K McPherson,Dennis E. Danley,R W Stevenson,E J Barrett,Judith L. Treadway +8 more
TL;DR: Findings support the use of CP-91149 in investigating glycogenolytic versus gluconeogenic flux in hepatic glucose production, and demonstrate that glycogenical phosphorylase inhibitors may be useful in the treatment of type 2 diabetes.
Patent
Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
TL;DR: In this paper, the indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof thereof, wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, C(O)NR8R9 or C (O)R12, useful as inhibitors of glycogen phosphorylase, methods of treating GPs dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.
Journal ArticleDOI
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia.
David E. Johnson,Hanae Yamazaki,Karen M. Ward,Anne W. Schmidt,Wesley S. Lebel,Judith L. Treadway,E. Michael Gibbs,Walter S. Zawalich,Hans Rollema +8 more
TL;DR: It is demonstrated that low concentrations of olanzapine and clozapine can markedly and selectively impair cholinergic-stimulated insulin secretion by blocking muscarinic M3 receptors, which could be one of the contributing factors to their higher risk for producing hyperglycemia and diabetes in humans.